We and others previously demonstrated that PARP inhibitors are effective in treatment of homologous recombination defective (HRD) cancers (6,7) and currently four different PARP inhibitors are approved for treating several HRD cancers. Here, PARP1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.